Business
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\nBoth leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors\n\n\nCompany reminds shareholders to vote today to protect the value of their investment and ensure Aurinia’s continued momentum\n\n\nCompany to release first quarter financial and operational results on May 4, 2023\n\n\nShareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at [email protected]\n\n\n EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that Aurinia shareholders vote FOR the re-election of all eight incumbent directors to the Board of Directors (the “Board”) at the Company’s 2023 Annual General Meeting (the “Meeting”).\n\n\nISS’ positive recommendation follows an April 26 report from Glass Lewis, another leading independent proxy advisor, which also recommended that shareholders vote for the re-election of all incumbent directors.\n\n\nAurinia is pleased that ISS and Glass Lewis recognize the Board and management’s pivotal role in the Company’s continued growth and momentum. Aurinia’s Board also appreciates the feedback and continued strong support of our shareholders.\n\n\nAurinia’s Board and management are taking the right steps to maximize shareholder value.\n\n\nAurinia is well-positioned for significant value enhancement. The Company continues to build upon its robust sales growth – with net sales increasing over 194% in 2022 – and is making significant progress in expanding LUPKYNIS’ availability in international markets in partnership with Otsuka.\n\n\nIn 2022, LUPKYNIS received approvals in the UK and EU and launched in several EU countries. Our efforts to gain regulatory approval in Japan remain on track, and we continue to expect a PMDA submission in the back half of 2023. We believe that our commercialization efforts will continue to unlock significant value for shareholders.\n\n\nEach member of the Board has played an integral role in our progress to date. Our directors have the expertise need...